Aeglea Bio Therapeutics (NASDAQ:AGLE)‘s stock had its “outperform” rating reiterated by stock analysts at BMO Capital Markets in a note issued to investors on Wednesday. They presently have a $18.00 price objective on the biotechnology company’s stock. BMO Capital Markets’ target price would suggest a potential upside of 95.65% from the company’s previous close.
Separately, Zacks Investment Research lowered Aeglea Bio Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, January 9th. One research analyst has rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $11.83.
Shares of Aeglea Bio Therapeutics (AGLE) traded up $0.72 during midday trading on Wednesday, hitting $9.20. The stock had a trading volume of 35,218 shares, compared to its average volume of 87,897. Aeglea Bio Therapeutics has a twelve month low of $2.81 and a twelve month high of $9.33. The stock has a market capitalization of $144.10, a price-to-earnings ratio of -4.71 and a beta of 1.38.
TRADEMARK VIOLATION WARNING: This report was first posted by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://www.americanbankingnews.com/2018/03/14/bmo-capital-markets-trims-aeglea-bio-therapeutics-agle-target-price-to-18-00.html.
Aeglea Bio Therapeutics Company Profile
Aeglea BioTherapeutics, Inc is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine.
Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.